[Form 4] CAMP4 Therapeutics Corporation Insider Trading Activity
Camp4 Therapeutics insider Kelly Gold, who serves as Chief Financial Officer, purchased 6,060 shares of Camp4 common stock at $1.65 per share in a private placement dated September 11, 2025. After the transaction, the reporting person beneficially owned 67,877 shares. The purchase was made pursuant to a Securities Purchase Agreement executed by the company, certain institutional investors, and participating directors, employees, and consultants.
This disclosure is a routine Section 16 filing showing an officer buy in a private placement rather than an open-market trade. It documents insider participation alongside institutional investors but does not provide additional financial, valuation, or company-operational context in this filing.
Camp4 Therapeutics insider Kelly Gold, che svolge la funzione di Chief Financial Officer, ha acquistato 6.060 azioni ordinarie di Camp4 a 1,65$ per azione in una private placement datata 11 settembre 2025. Dopo la transazione, la persona reportante possedeva 67.877 azioni. L’acquisto è stato effettuato ai sensi di un Securities Purchase Agreement stipulato dall’azienda, da alcuni investitori istituzionali e da direttori, dipendenti e consulenti partecipanti.
Questa divulgazione è una routine di filing della Sezione 16 che mostra un acquisto da parte di un dirigente in una private placement piuttosto che in una negoziazione sul mercato aperto. Documenta la partecipazione degli insider accanto agli investitori istituzionali ma non fornisce ulteriori contesti finanziari, di valutazione o operativi dell’azienda in questa filing.
Camp4 Therapeutics insider Kelly Gold, que funge como Directora Financiera, compró 6.060 acciones comunes de Camp4 a $1,65 por acción en una colocación privada fechada el 11 de septiembre de 2025. Después de la transacción, la persona informante posuía 67.877 acciones. La compra se realizó conforme a un Securities Purchase Agreement suscrito por la empresa, ciertos inversores institucionales y directores, empleados y consultores participantes.
Esta divulgación es un informe rutinario de la Sección 16 que muestra una compra por parte de un ejecutivo en una colocación privada en lugar de una operación en el mercado abierto. Documenta la participación de insiders junto a inversores institucionales, pero no proporciona contexto financiero, de valoración ni operativo adicional en este expediente.
Camp4 Therapeutics의 내부자 켈리 골드가 최고재무책임자(CFO)로 재직하며 2025년 9월 11일 비공개 배정(private placement)에서 주당 1.65달러에 Camp4 보통주 6,060주를 매입했습니다. 거래 후 보고자 본인은 67,877주의 지분을 보유하게 되었습니다. 이 매수는 회사, 일부 기관 투자자 및 참가 이사, 직원 및 컨설턴트가 참여한 증권 매입 계약에 따라 이루어졌습니다.
이 공시는 비공개 배정에서의 임원 매수를 보여주는 일반적인 섹션 16 신고로서, 공개 시장 거래가 아니라 insider 참여를 문서화하지만 이 서류에서 추가적인 재무, 평가 또는 회사 운영 맥락은 제공하지 않습니다.
Camp4 Therapeutics insider, Kelly Gold, qui occupe le poste de directeur financier, a acheté 6 060 actions ordinaires de Camp4 à 1,65 $ par action lors d'un placement privé daté du 11 septembre 2025. Après la transaction, la personne déclarant détenait de manière bénéficiaire 67 877 actions. L'achat a été effectué conformément à un accord d'achat de titres signé par l'entreprise, certains investisseurs institutionnels et des administrateurs, employés et consultants participants.
Cette divulgation est une communication routinière de la Section 16 montrant l'achat d’un cadre dans un placement privé plutôt que dans une opération sur le marché. Elle documente la participation des initiés aux côtés des investisseurs institutionnels mais ne fournit pas de contexte financier, d’évaluation ou opérationnel supplémentaire dans ce dossier.
Camp4 Therapeutics-Insider Kelly Gold, der als Chief Financial Officer fungiert, kaufte 6.060 Stammaktien von Camp4 zu 1,65 USD pro Aktie in einer Privatplatzierung datiert auf den 11. September 2025. Nach der Transaktion besaß die meldende Person nutzbringend 67.877 Aktien. Der Kauf erfolgte gemäß einem Securities Purchase Agreement, das von dem Unternehmen, bestimmten institutionellen Investoren sowie teilnehmenden Direktoren, Mitarbeitern und Beratern unterzeichnet wurde.
Diese Offenlegung ist eine routinemäßige Section-16-Anmeldung, die einen Insiderkauf in einer Privatplatzierung statt eines Handels an der Börse zeigt. Sie dokumentiert die Teilnahme von Insidern neben institutionellen Investoren, liefert jedoch keinen zusätzlichen finanziellen, Bewertungs- oder betriebsbezogenen Kontext in diesem Bericht.
Camp4 Therapeutics المبلغ عنه داخلياً كيلي جولد، التي تشغل منصب المدير المالي، اشترت 6,060 سهماً عاديًا من Camp4 بسعر 1.65 دولارًا للسهم في صفقة طرح خاص بتاريخ 11 سبتمبر 2025. بعد الصفقة، امتلكت الشخص المبلغ عنه بشكل مستفيد 67,877 سهماً. تمت عملية الشراء وفقاً لاتفاق شراء أوراق مالية موقع من الشركة وبعض المستثمرين المؤسسيين والمديرين المشاركين والموظفين والمستشارين المشاركين.
هذه الإفصاح هو ملف روتيني وفق القسم 16 يظهر شراء من موظف في طرح خاص بدلاً من تداول في السوق المفتوحة. يوثق مشاركة المطلعين جنباً إلى جنب مع المستثمرين المؤسسيين لكنه لا يوفر سياقاً مالياً إضافياً أو تقييماً أو سياقاً تشغيلياً للشركة في هذا الملف.
Camp4 Therapeutics 内部人士凯利·戈德，担任首席财务官，在2025年9月11日的私募配售中以每股$1.65购买了6,060股Camp4普通股。交易后，报告人受益地拥有67,877股。此次购买依据公司、若干机构投资者以及参与的董事、员工和顾问共同签署的证券购买协议执行。
本披露属于常规的第16条 filing，显示高管在私募中的买入而非在公开市场交易。它记录了内部人和机构投资者的参与，但在本次 filing 中并未提供额外的财务、估值或公司运营背景信息。
- Insider purchase: CFO acquired 6,060 shares, which can be interpreted as management buying equity.
- Transparent disclosure: Transaction reported on Form 4 with post-transaction ownership of 67,877 shares.
- Participation in private placement: Purchase executed under a Securities Purchase Agreement alongside institutional investors and other insiders.
- Limited context: Filing discloses the trade but provides no information on company valuation, total outstanding shares, or materiality of the purchase.
- Private placement terms not detailed: The form does not include aggregate size of the placement or whether there are lock-up or transfer restrictions.
Insights
TL;DR: Officer purchased a modest number of shares in a private placement at $1.65, increasing insider ownership to 67,877 shares.
This Form 4 reports a non-derivative acquisition by the company CFO for 6,060 shares at $1.65 per share in a private placement that included institutional investors and other insiders. Such purchases can signal management confidence but the filing alone lacks scale context versus total outstanding shares or dollar amount relative to compensation, so materiality for valuation is unclear from this form alone.
TL;DR: Transaction is properly disclosed and shows insider participation in a company private placement alongside institutional investors.
The disclosure indicates the purchase was executed under a Securities Purchase Agreement involving the issuer and specified investors, which is appropriate for a private placement. The filing identifies the reporting person as an officer and provides post-transaction beneficial ownership. The form contains no indication of any exception or omission regarding the required Section 16 reporting obligations.
Camp4 Therapeutics insider Kelly Gold, che svolge la funzione di Chief Financial Officer, ha acquistato 6.060 azioni ordinarie di Camp4 a 1,65$ per azione in una private placement datata 11 settembre 2025. Dopo la transazione, la persona reportante possedeva 67.877 azioni. L’acquisto è stato effettuato ai sensi di un Securities Purchase Agreement stipulato dall’azienda, da alcuni investitori istituzionali e da direttori, dipendenti e consulenti partecipanti.
Questa divulgazione è una routine di filing della Sezione 16 che mostra un acquisto da parte di un dirigente in una private placement piuttosto che in una negoziazione sul mercato aperto. Documenta la partecipazione degli insider accanto agli investitori istituzionali ma non fornisce ulteriori contesti finanziari, di valutazione o operativi dell’azienda in questa filing.
Camp4 Therapeutics insider Kelly Gold, que funge como Directora Financiera, compró 6.060 acciones comunes de Camp4 a $1,65 por acción en una colocación privada fechada el 11 de septiembre de 2025. Después de la transacción, la persona informante posuía 67.877 acciones. La compra se realizó conforme a un Securities Purchase Agreement suscrito por la empresa, ciertos inversores institucionales y directores, empleados y consultores participantes.
Esta divulgación es un informe rutinario de la Sección 16 que muestra una compra por parte de un ejecutivo en una colocación privada en lugar de una operación en el mercado abierto. Documenta la participación de insiders junto a inversores institucionales, pero no proporciona contexto financiero, de valoración ni operativo adicional en este expediente.
Camp4 Therapeutics의 내부자 켈리 골드가 최고재무책임자(CFO)로 재직하며 2025년 9월 11일 비공개 배정(private placement)에서 주당 1.65달러에 Camp4 보통주 6,060주를 매입했습니다. 거래 후 보고자 본인은 67,877주의 지분을 보유하게 되었습니다. 이 매수는 회사, 일부 기관 투자자 및 참가 이사, 직원 및 컨설턴트가 참여한 증권 매입 계약에 따라 이루어졌습니다.
이 공시는 비공개 배정에서의 임원 매수를 보여주는 일반적인 섹션 16 신고로서, 공개 시장 거래가 아니라 insider 참여를 문서화하지만 이 서류에서 추가적인 재무, 평가 또는 회사 운영 맥락은 제공하지 않습니다.
Camp4 Therapeutics insider, Kelly Gold, qui occupe le poste de directeur financier, a acheté 6 060 actions ordinaires de Camp4 à 1,65 $ par action lors d'un placement privé daté du 11 septembre 2025. Après la transaction, la personne déclarant détenait de manière bénéficiaire 67 877 actions. L'achat a été effectué conformément à un accord d'achat de titres signé par l'entreprise, certains investisseurs institutionnels et des administrateurs, employés et consultants participants.
Cette divulgation est une communication routinière de la Section 16 montrant l'achat d’un cadre dans un placement privé plutôt que dans une opération sur le marché. Elle documente la participation des initiés aux côtés des investisseurs institutionnels mais ne fournit pas de contexte financier, d’évaluation ou opérationnel supplémentaire dans ce dossier.
Camp4 Therapeutics-Insider Kelly Gold, der als Chief Financial Officer fungiert, kaufte 6.060 Stammaktien von Camp4 zu 1,65 USD pro Aktie in einer Privatplatzierung datiert auf den 11. September 2025. Nach der Transaktion besaß die meldende Person nutzbringend 67.877 Aktien. Der Kauf erfolgte gemäß einem Securities Purchase Agreement, das von dem Unternehmen, bestimmten institutionellen Investoren sowie teilnehmenden Direktoren, Mitarbeitern und Beratern unterzeichnet wurde.
Diese Offenlegung ist eine routinemäßige Section-16-Anmeldung, die einen Insiderkauf in einer Privatplatzierung statt eines Handels an der Börse zeigt. Sie dokumentiert die Teilnahme von Insidern neben institutionellen Investoren, liefert jedoch keinen zusätzlichen finanziellen, Bewertungs- oder betriebsbezogenen Kontext in diesem Bericht.
FAQ
What transaction did Kelly Gold report on the CAMP Form 4?
How many Camp4 shares does the reporting person own after this transaction?
Was this acquisition an open-market trade or a private placement?
What role does the reporting person have at Camp4?
Does the Form 4 show any derivative transactions by the reporting person?
